Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 3/20 | 0.48 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2081318 | 1.00 | MEN1 (0.53) | MEN1KMT2AOPRD1NAMPTNR1D1 | |
| SCHEMBL31359949 | 1.00 | MEN1 (0.53) | MEN1KMT2AOPRD1NAMPTNR1D1 | |
| SCHEMBL31158720 | 1.00 | MEN1 (0.53) | MEN1KMT2AOPRD1NAMPTNR1D1 | |
| SCHEMBL2082826 | 1.00 | MEN1 (0.53) | MEN1KMT2AOPRD1NAMPTNR1D1 | |
| SCHEMBL30299421 | 1.00 | MEN1 (0.53) | MEN1KMT2AOPRD1NAMPTNR1D1 | |
| SCHEMBL18914431 | 0.89 | OPRD1 (0.48) | MEN1KMT2AOPRD1NAMPTNR1D1 | |
| SCHEMBL27406117 | 0.89 | OPRD1 (0.50) | MEN1KMT2AOPRD1NAMPTNR1D1 | |
| SCHEMBL10207323 | 0.89 | OPRD1 (0.50) | MEN1KMT2AOPRD1NAMPTNR1D1 | |
| SCHEMBL5570014 | 0.88 | OPRD1 (0.52) | MEN1KMT2AOPRD1NAMPTNR1D1 | |
| SCHEMBL5064869 | 0.88 | OPRD1 (0.49) | MEN1KMT2AOPRD1NAMPTNR1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117586170-B | Indolinyl acyl derivative and synthetic method of isoquinoline formyl derivative | 江苏集萃分子工程研究院有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-117586170-A | Indolinyl acyl derivative and synthetic method of isoquinoline formyl derivative | 江苏集萃分子工程研究院有限公司 | 2024-02-23 | — | — | CN | claimed |
| WO-2009130015-A1 | IMPROVED RAF INHIBITORS | GPC BIOTECH AG (DE) | 2009-10-29 | — | — | WO | claimed |
| CN-117586170-B | Indolinyl acyl derivative and synthetic method of isoquinoline formyl derivative | 江苏集萃分子工程研究院有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117586170-A | Indolinyl acyl derivative and synthetic method of isoquinoline formyl derivative | 江苏集萃分子工程研究院有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| WO-2021126999-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-11028101-B2 | 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY LTD (AU) | 2021-06-08 | — | — | US | disclosed |
| US-10947234-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-03-16 | — | — | US | disclosed |
| EP-3426351-B1 | BENZOPIPERIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2020-12-09 | — | — | EP | disclosed |
| US-20200361931-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-11-19 | — | — | US | disclosed |
| US-20070265301-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-15 | — | — | US | disclosed |
| US-20070265301-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-15 | — | — | US | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2005113510-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-01 | — | — | WO | disclosed |
| EP-1598341-A1 | DPP-IV inhibitors | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) | 2005-11-23 | — | — | EP | disclosed |
| EP-1149079-B1 | TETRAHYDRO ISOQUINO LINEALKANOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SK CORP (KR) | 2004-04-21 | — | — | EP | disclosed |
| EP-1149079-A1 | TETRAHYDRO ISOQUINO LINEALKANOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SK Corporation (KR) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000046204-A1 | TETRAHYDRO ISOQUINO LINEALKANOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SK CORPORATION (KR) | 2000-08-10 | — | — | WO | disclosed |
| US-5955471-A | USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, INCLUDING DEPRESSION | SK CORPORATION (US) | 1999-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361931-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | MEN1 898/4885KMT2A 67/4885OPRD1 4383/4885 |
| US-11028101-B2 | 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies | HBB, HBZ, HBG2 | MEN1 362/4885KMT2A 110/4885OPRD1 127/4885 |
| US-20070265301-A1 | Dpp-IV Inhibitors | DPP4, DPP8, DPP7 | MEN1 1376/4885KMT2A 1722/4885OPRD1 1112/4885 |
| US-10947234-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | MEN1 898/4885KMT2A 67/4885OPRD1 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.